藥 物 回 收
|
| |
| The United States: FDA announces voluntary recall of Montelukast tablets by Camber Pharmaceuticals due to incorrect drug in bottles (English Only) |
| |
The US Food and Drug Administration (FDA) announces that Camber Pharmaceuticals, Inc., Piscataway, N.J. is initiating a voluntary recall of one lot of its product, Montelukast Sodium Tablets – lot number MON17384, expiration 12/31/2019. Sealed bottles labeled as montelukast sodium tablets, 10 milligram, 30-count bottle from Camber were found to instead contain 90 tablets of Losartan Potassium Tablets, 50 mg.
This tablet mix-up may pose a safety risk as taking losartan tablets when not prescribed has the potential to cause renal dysfunction, elevated potassium levels and low blood pressure. This risk is especially high for pregnant women taking the allergy and asthma medication montelukast because losartan, which is indicated to treat high blood pressure, could harm or kill the fetus.
Please refer to the following website in FDA for details:
http://www.fda.gov/NewsEvents/Newsroom/../ucm619174.htm
In Hong Kong, the above product is not a registered pharmaceutical product.
Ends/ Saturday, September 1, 2018
Issued at HKT 13:30
|
| |
